Latest Lorcaserin Stories
On June 27th, 2012, the US FDA approved the new diet pill Belviq. Belviq (lorcaserin), by Arena Pharmaceuticals, is the first weight-loss drug to be approved in 13 years, according to Reuters. In the briefing documents for the May 10th, 2012 FDA Endocrinologic and Metabolic Drugs Advisory Committee, reviewers expressed concerns on safety of Lorcaserin related mainly to heart problems. Another obesity drug, the popular Fen Phen, was withdrawn from the market in 1997; it was linked with...
SAN DIEGO, July 5, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the promotion of Craig M. Audet to the position of Senior Vice President, Operations and Head of Global Regulatory Affairs. In his new role, Audet will serve as an executive officer of the company. Audet, 48, will oversee various operations at Arena, including investor relations and alliance management, and will continue to lead regulatory affairs. He joined the company in April 2011...
Connie K. Ho for redOrbit.com 78 million. This is the number of people who are obese in the United States, according to the U.S. Center for Disease Control and Prevention (CDC). Obesity increases the risk of diabetes, heart attacks, and strokes. It also costs the U.S. economy $147 billion a year in expenses and lost productivity. With these dire facts in mind, the Food and Drug Administration (FDA) recently approved the anti-obesity prescription drug Belviq from Arena Pharmaceuticals to be...
WASHINGTON, June 27, 2012 /PRNewswire-USNewswire/ -- Today, members of the Obesity Care Continuum (OCC) applauded the Food and Drug Administration's (FDA) approval of a new obesity drug - Belviq (lorcaserin HCl). Belviq is the first obesity drug to be approved in the past 13 years. "This is a tremendous step forward in addressing our most pressing health problem. Healthcare professionals now have a new option to help their patients affected by obesity manage this chronic condition....
SAN DIEGO and WOODCLIFF LAKE, N.J., June 27, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BELVIQ (pronounced BEL-VEEK) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2( )or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at...
Study shows potential weight-loss medication helps overweight patients with diabetes SILVER SPRING, Md., June 26, 2012 /PRNewswire-USNewswire/ -- A new study on the effects of lorcaserin, a drug recently recommended for approval by an FDA advisory panel for the treatment of obesity, was just published in the scientific journal Obesity. The journal is published by The Obesity Society (TOS), the leading scientific organization in North America dedicated to the study of obesity....
On June 27th, 2012, the US FDA is set to decide on new obesity drug Lorcaserin. In the briefing documents for the May 10th, 2012 meeting of the FDA Endocrinologic and Metabolic Drugs Advisory Committee, reviewers expressed concerns on safety of Lorcaserin related mainly to heart problems. The FDA originally declined to approve the drug in 2010 because of concerns including potential effects on patients' hearts. Another obesity drug, the popular Fen Phen, was withdrawn from the market...
SAN DIEGO, May 21, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of an underwritten public offering of 12,650,000 shares of its common stock, including 1,650,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares were offered by Arena at a price to the public of $5.50 per share. The gross proceeds to Arena from this offering were approximately $69.6 million,...
SAN DIEGO, May 16, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock, offered at a price to the public of $5.50 per share. The gross proceeds to Arena from this offering are expected to be $60.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Arena. Arena has granted the underwriters a 30-day option to...
SAN DIEGO, May 15, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies & Company, Inc. and Piper Jaffray & Co. are acting as joint book-running managers for the offering. BMO...
